Yes...and they do. You just have to acknowlege that we are not employees , management or sit on the BOD. There is never enough information in SEC docs or news releases, as much as we would like, but the confrences that Dr. Ji has participated in revealed new things. The Irael conference that Mark R. Brunswick, Ph.D SVP - Regulatory Affairs, participated in had several eye opening comments some that were only a few words but powerful. leaked informatio wanders in from time to time such as the UPS testing.
The question I put forth is what information are you looking for?
Look at the pipeline, the Carreer opportunities, the press releases of which there are many more than these:
Feb 27, 2020 Sorrento to Provide Corporate Update
May 08, 2020 Sorrento And Mount Sinai Health Jointly Develop COVI-SHIELD™
May 15, 2020 STI-1499, A Potent Anti-SARS-CoV-2 Antibody
May 21, 2020 Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib
Jun 10, 2020 Sorrento Announces EUA Application COVI-TRACK Diagnostic Test
Jun 12, 2020 Sorrento Announces Full Repayment of Outstanding Term Loans
Jul 24, 2020 Sorrento Enters Into Letter Of Intent To Acquire SmartPharm
Aug 19, 2020 Sorrento Announces FDA IND Filing Today for COVI-GUARD
Sep 02, 2020 Sorrento Announces the Closing of Its Acquisition of SmartPharm
Sep 14, 2020 Sorrento Secures Exclusive License From Mayo Clinic
Sep 16, 2020 Sorrento Receives US FDA Clearance Phase 1 Clinical Trial of STI-1499
Oct 07, 2020 Sorrento Announces the Discovery of Salicyn-30
Oct 12, 2020 Sorrento Adds Mesenchymal Stem Cell Program (MSC)
Oct 14, 2020 Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib
Nov 09, 2020 Sorrento Announces FDA IND Filing Today for COVI-AMG
Nov 11, 2020 Sorrento Announces IND Filing for COVI-DROPS
Nov 27, 2020 DARPA and JPEO Award Contract to SmartPharm
Dec 08, 2020 Sorrento Receives Licensure From the State of California for Clinical Testing Laboratory (CLIA)
Dec 09, 2020 Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG)
Dec 22, 2020 Sorrento Announces It Has Submitted EUA Application to the FDA for COVI-STIX™
Dec 30, 2020 Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX™
Jan 31, 2021 Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells
Feb 08, 2021 Sorrento Announces Subsidiary Company - ADNAB, Inc
Mar 01, 2021 Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301
Mar 02, 2021 Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099, Intranasal COVIDROPS
Mar 07, 2021 Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
Mar 09, 2021 Sorrento and Mount Sinai Health System Enter Into Exclusive License Agreement
February 24, 2021, Sorrento Therapeutics, Inc. (“Sorrento”) and ANP Technologies, Inc. (“ANP”) entered into a binding term sheet
I know we all can keep a secret so the BOD and management should lay their plans bare for us to see and with the knowledge the competition would never find out so they could disrupt Sorrentos plans...right???
News 
Market Data 
Discover 
